Src- and Abl-kinases are thought to have distinct inactive conformations, accounting for differential responses to the drug imantinib, used to treat chronic myeloid leukemia. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.